Clinical Trial Update: Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on abemaciclib (LY2835219) in patients with recurrent primary brain tumors; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Brain Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING